Abcam, ab108805, Human Apolipoprotein AII ELISA Kit (APOA2)

Size: 1 x 96Tests
Human Apolipoprotein AII ELISA Kit (APOA2) is a Sandwich (quantitative) ELISA for the measurement of Human Apolipoprotein AII (APOA2) in Human in Biofluids samples.
Key facts
Detection method:Colorimetric,
Sample types:Plasma, Serum,
Reacts with:Human,
Assay type:Sandwich (quantitative),
Sensitivity:= 0.2 µg/mL,
Range:0.5 - 32 µg/mL,
Assay time:4h,
Assay Platform:Microplate

Product details:
Abcam's Apolipoprotein AII (APOA2) Human
in vitro
ELISA (Enzyme-Linked Immunosorbent Assay) kit is designed for the quantitative measurement of apolipoprotein AII concentrations in plasma, serum, cell culture, cell lysates and tissue samples.
An Apolipoprotein AII specific antibody has been precoated onto 96-well plates and blocked. Standards or test samples are added to the wells and subsequently an Apolipoprotein AII specific biotinylated detection antibody is added and then followed by washing with wash buffer. Streptavidin-Peroxidase Complex is added and unbound conjugates are washed away with wash buffer. TMB is then used to visualize Streptavidin-Peroxidase enzymatic reaction. TMB is catalyzed by Streptavidin-Peroxidase to produce a blue color product that changes into yellow after adding acidic stop solution. The density of yellow coloration is directly proportional to the amount of Apolipoprotein AII captured in plate.
Get better reproducibility in only 90 minutes with Human Apolipoprotein AII ELISA Kit (
ab184859
) from our SimpleStep ELISA
range.
The entire kit may be stored at -20°C for long term storage before reconstitution - Avoid repeated freeze-thaw cycles.

Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions-Multi, Storage information-Please refer to protocols

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Apolipoprotein A-II (also known as ApoA-II or Apolipoprotein A2) is a pivotal protein component of high-density lipoproteins (HDL) in the plasma. It is encoded by the APOA2 gene in humans and displays a molecular mass of approximately 17.4 kDa. Apolipoprotein A-II is primarily expressed in the liver and secreted into the bloodstream where it plays a direct role in lipid metabolism. Its structural composition includes a highly amphipathic α-helical structure that facilitates interaction with lipids aiding in lipoprotein formation and stability.
Biological function summary
Apolipoprotein A-II serves as a significant regulator of HDL metabolism and lipid transport. It is an integral part of HDL particles contributing to their stability and function. Apolipoprotein A-II influences lecithin-cholesterol acyltransferase (LCAT) activity which affects cholesterol esterification. Although less studied than its counterpart Apolipoprotein A-I ApoA-II's interaction with lipids and proteins such as CETP (cholesteryl ester transfer protein) suggests its involvement in lipid exchange and reverse cholesterol transport processes.
Pathways
Apolipoprotein A-II impacts the reverse cholesterol transport pathway and lipid metabolic processes. ApoA-II works closely with its relative Apolipoprotein A-I both part of the same HDL complex. Together they play essential roles in maintaining cholesterol homeostasis and promoting cholesterol efflux from cells back to the liver. The mechanism by which it modulates the function of lipoprotein lipase and hepatic lipase further implicates its role in lipid metabolism and energy balance processes.
Dysfunction or abnormal levels of Apolipoprotein A-II have associations with cardiovascular diseases and metabolic syndromes. Altered ApoA-II levels correlate with an increased risk of atherosclerosis as its imbalance can drive perturbations in HDL composition and function. Moreover research links Apolipoprotein A-II with insulin resistance linking it with ApoA-I imbalanced lipid transport and metabolism in obesity and diabetes contexts. Understanding these connections may guide therapeutic strategies targeting ApoA-II to mitigate the risks and progression of these disorders.